Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. The company reported quarterly sales of $14.503 million which beat the analyst consensus estimate of $13.963 million by 3.87 percent. This is a 39.22 percent increase over sales of $10.417 million the same period last year.
Theravance Biopharma Q1 2024 GAAP EPS $(0.24) Beats $(0.25) Estimate, Sales $14.503M Beat $13.963M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.